

TNHAN

April 23, 2021

ACIP Lifts Pause on the Administration of Janssen/Johnson & Johnson Vaccines

Please see the full media release here: <https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough>

Providers with current inventory of the Janssen/Johnson & Johnson vaccine may resume its administration in individuals ages 18 years and older. Women between the ages of 18 and 49 years of age should be made aware of the risk of rare but serious vaccine-induced immune thrombotic thrombocytopenia (VITT) associated with the use of this product when deciding to receive the Janssen/Johnson & Johnson vaccine versus the mRNA vaccines from Pfizer and Moderna, which have not been associated with this rare blood clotting disorder.

CDC updates on the Janssen/Johnson & Johnson COVID-19 vaccine will be posted here: [Johnson & Johnson's Janssen COVID-19 Vaccine Overview and Safety | CDC](#) later this evening.

Clinicians should continue to obtain a history of COVID-19 vaccination from patients with suspected thrombotic events. Recommendations for evaluation may be found at [Vaccine-induced Immune Thrombotic Thrombocytopenia - Hematology.org](#)